KR20190046895A - 신경퇴행성 질환의 치료를 위한 니코틴아미드 리보사이드 및 프테로스틸렌 조성물 및 방법 - Google Patents

신경퇴행성 질환의 치료를 위한 니코틴아미드 리보사이드 및 프테로스틸렌 조성물 및 방법 Download PDF

Info

Publication number
KR20190046895A
KR20190046895A KR1020197008293A KR20197008293A KR20190046895A KR 20190046895 A KR20190046895 A KR 20190046895A KR 1020197008293 A KR1020197008293 A KR 1020197008293A KR 20197008293 A KR20197008293 A KR 20197008293A KR 20190046895 A KR20190046895 A KR 20190046895A
Authority
KR
South Korea
Prior art keywords
composition
dose
nicotinamide riboside
composition comprises
thermostyrene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197008293A
Other languages
English (en)
Korean (ko)
Inventor
에릭 알렉산더 마르코튤리
다니엘 안토니오 앨미나나
Original Assignee
엘리시움 헬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘리시움 헬스, 인크. filed Critical 엘리시움 헬스, 인크.
Publication of KR20190046895A publication Critical patent/KR20190046895A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020197008293A 2016-08-22 2017-08-22 신경퇴행성 질환의 치료를 위한 니코틴아미드 리보사이드 및 프테로스틸렌 조성물 및 방법 Ceased KR20190046895A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378053P 2016-08-22 2016-08-22
US62/378,053 2016-08-22
PCT/US2017/047979 WO2018039207A1 (en) 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
KR20190046895A true KR20190046895A (ko) 2019-05-07

Family

ID=61246253

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008293A Ceased KR20190046895A (ko) 2016-08-22 2017-08-22 신경퇴행성 질환의 치료를 위한 니코틴아미드 리보사이드 및 프테로스틸렌 조성물 및 방법

Country Status (12)

Country Link
US (2) US11260069B2 (https=)
EP (1) EP3500267A4 (https=)
JP (1) JP7132907B2 (https=)
KR (1) KR20190046895A (https=)
CN (2) CN115645432A (https=)
AU (1) AU2017316614B2 (https=)
BR (1) BR112019003579A2 (https=)
CA (1) CA3034673A1 (https=)
MX (1) MX2019002211A (https=)
RU (1) RU2019108100A (https=)
WO (1) WO2018039207A1 (https=)
ZA (1) ZA201901536B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500267A4 (en) 2016-08-22 2020-03-18 Elysium Health, Inc. NICOTINAMIDRIBOSIDE AND PTEROSTILLE COMPOSITIONS AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES
WO2018213715A1 (en) * 2017-05-18 2018-11-22 Elysium Health, Inc. Methods and compositions for improving sleep
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
WO2019023471A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND INVERTING THE ASPECTS OF AGING
US20220072019A1 (en) * 2018-10-19 2022-03-10 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2020102326A1 (en) * 2018-11-13 2020-05-22 Elysium Health, Inc Methods for determining and increasing nad levels
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
WO2020176445A1 (en) * 2019-02-26 2020-09-03 Universitat De Valencia-Estudi General Methods and compositions for treating motor neuron diseases
CN110812365A (zh) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 一种组合物及其制备方法与制剂
CN111838669B (zh) * 2020-08-07 2022-11-29 四川大学华西医院 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
EP4079311B1 (en) 2021-04-20 2025-10-01 Nuvamid SA Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
WO2022269064A1 (en) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
EP4284387B1 (en) 2021-06-24 2024-07-31 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
WO2023076804A1 (en) * 2021-10-27 2023-05-04 Elysium Health Inc. Methods for treatment of menopausal syndromes
CN121793959A (zh) 2023-06-14 2026-04-03 可劳迈戴斯有限公司 静脉内配制品中的烟酰胺核苷及其衍生物与使用方法
CN116807985A (zh) * 2023-06-20 2023-09-29 风火轮(上海)生物科技有限公司 一种烟酰胺核糖组合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20090163580A1 (en) * 2007-12-24 2009-06-25 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
US9737495B2 (en) 2009-06-22 2017-08-22 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US9439875B2 (en) 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
EP2574339A1 (de) * 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
US20130149277A1 (en) 2011-12-13 2013-06-13 Cliffstar Llc Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
US20130296440A1 (en) * 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
KR20220098049A (ko) * 2013-10-30 2022-07-08 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
JP2017518306A (ja) 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
WO2016122832A1 (en) * 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
US20180071273A1 (en) * 2015-03-17 2018-03-15 Speccialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
EP3500267A4 (en) 2016-08-22 2020-03-18 Elysium Health, Inc. NICOTINAMIDRIBOSIDE AND PTEROSTILLE COMPOSITIONS AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES

Also Published As

Publication number Publication date
WO2018039207A1 (en) 2018-03-01
CA3034673A1 (en) 2018-03-01
US20190201426A1 (en) 2019-07-04
AU2017316614B2 (en) 2023-06-15
EP3500267A4 (en) 2020-03-18
JP7132907B2 (ja) 2022-09-07
AU2017316614A1 (en) 2019-03-21
US11260069B2 (en) 2022-03-01
RU2019108100A (ru) 2020-09-22
US20220143055A1 (en) 2022-05-12
ZA201901536B (en) 2024-06-26
EP3500267A1 (en) 2019-06-26
BR112019003579A2 (pt) 2019-05-21
CN109982706A (zh) 2019-07-05
MX2019002211A (es) 2019-10-30
US11998561B2 (en) 2024-06-04
JP2019524856A (ja) 2019-09-05
CN115645432A (zh) 2023-01-31
RU2019108100A3 (https=) 2020-11-27

Similar Documents

Publication Publication Date Title
US11998561B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
AU2020286208B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
CA3105341C (en) Methods of normalizing amino acid metabolism
DK2900230T3 (en) RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
BRPI0807735A2 (pt) Composição farmacêutica composta de trigonelina e 4-hidroxiisoleucina e o processo da mesma
US20140112983A1 (en) Nitrite compositions and uses thereof
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
WO2022157798A1 (en) Synergistic nutritional compositions for treating neurocognitive disorders
HK1254169B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
HK1254169A1 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
HK40052619A (en) Methods of normalizing amino acid metabolism
BR112017026642B1 (pt) Composições de ribosídeo de nicotinamida e pteroestilbeno e seus usos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190321

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220706

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220913

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220706

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I